Influence of the results of international studies on the choice of treatment tactics for unresectable forms of squamous cell carcinoma of the head and neck
L. V. Bolotina,
T. I. Deshkina,
A. L. Kornietskaya,
S. A. Kravtsov,
T. V. Ustinova,
A. A. Paychadze,
A. D. Kaprin,
А. А. Fedenko https://doi.org/10.17650/2222-1468-2020-10-2-10-21
Abstract
The results of the clinical studies have a direct impact on clinical practice. The main criteria for the effectiveness of treatment method are increasing the overall life expectancy and improving its quality. In the treatment of common forms of squamous cell carcinoma of the head and neck, induction chemotherapy can be used, including platinum drugs, preferably in combination with cetuximab. Next immuno-oncological drugs should be prescribed. In the future, in the 1st line of therapy, it is possible to replace cetuximab with pembrolizumab or monotherapy with pembrolizumab, which allows to increase the effectiveness of treatment and reduce its toxicity. The article presents 3 clinical observations that demonstrate the possibility of integration the results of clinical research in practice.
About the Authors
L. V. Bolotina
P.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiology Center, Ministry of Health of Russia
Russian Federation
3 2 nd Botkinsky Dr., Moscow 125284
Russian Federation
3 2 nd Botkinsky Dr., Moscow 125284
T. I. Deshkina
P.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiology Center, Ministry of Health of Russia
Russian Federation
3 2 nd Botkinsky Dr., Moscow 125284
Russian Federation
3 2 nd Botkinsky Dr., Moscow 125284
A. L. Kornietskaya
P.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiology Center, Ministry of Health of Russia
Russian Federation
3 2 nd Botkinsky Dr., Moscow 125284
Russian Federation
3 2 nd Botkinsky Dr., Moscow 125284
S. A. Kravtsov
City Clinical Hospital No. 1, Moscow Healthcare Department
Russian Federation
17/1 Baumanskaya St., Moscow 105005
Russian Federation
17/1 Baumanskaya St., Moscow 105005
T. V. Ustinova
P.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiology Center, Ministry of Health of Russia
Russian Federation
3 2 nd Botkinsky Dr., Moscow 125284
Russian Federation
3 2 nd Botkinsky Dr., Moscow 125284
A. A. Paychadze
P.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiology Center, Ministry of Health of Russia
Russian Federation
3 2 nd Botkinsky Dr., Moscow 125284
Russian Federation
3 2 nd Botkinsky Dr., Moscow 125284
A. D. Kaprin
P.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiology Center, Ministry of Health of Russia
Russian Federation
3 2 nd Botkinsky Dr., Moscow 125284
Russian Federation
3 2 nd Botkinsky Dr., Moscow 125284
А. А. Fedenko
P.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiology Center, Ministry of Health of Russia
Russian Federation
3 2 nd Botkinsky Dr., Moscow 125284
Russian Federation
3 2 nd Botkinsky Dr., Moscow 125284
References
1. Beishon M. Too high or too low? ESMO’s clinical benefit scale fuels debate over approval thresholds. CancerWorld 2018;(81):5–11.
2. Breast Cancer. NCCN Clinical Practice Guidelines in Oncology, Version 3.2019. P. 68.
3. Ravaud A., Motzer R.J., Pandha H.S. et al. Adjuvant sunitinib in high risk renalcell carcinoma after nephrectomy. N Engl J Med 2016;375(23):417–27. DOI: 10.1056/NEJMoa1611406.
4. Baselga J., Campone M., Piccart M. et al. Everolimus in postmenopausal hormonereceptor-positive advanced breast cancer. N Engl J Med 2012;366(6):520–9. DOI: 10.1056/NEJMoa1109653.
5. Ghi M.G., Paccagnella A., Ferrari D. et al. Concomitant chemoradiation (CRT) or cetuximab/RT(CET/RT) versus induction docetaxel/cisplatin/5-fluorouracil (TPF) followed by CRT or CET/RT in patients with locally advanced squamous cell carcinoma of head and neck (LASCCHN). A randomized phase III factorial study (NCT01086826). J Clin Oncol 2014;32(15 Suppl):6004. DOI: 10.1200/jco.2014.32.15_suppl.6004.
6. Grose W.E., Lehane D.E., Dixon D.O. et al. Comparison of methotrexate and cisplatin for patients with advanced squamous cell carcinoma of the head and neck region: a southwest oncology group study. Cancer Treat Rep 1985;69(6):577–81.
7. Williams S.D., Velez-García E., Essessee I. et al. Chemotherapy for head and neck cancer: comparison of cisplatin + vinblastine + bleomycin versus methotrexate. Cancer 1986;57(1):18–23.
8. Forastiere A., Metch B., Schuller D.E. et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck. Southwest Oncology Group Study. J Clin Oncol 1992;10(8):1245–51. DOI: 10.1200/JCO.1992.10.8.1245.
9. Jacobs C., Lyman G., Velez-García E. et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992;10(2):257–63. DOI: 10.1200/JCO.1992.10.2.257.
10. Gibson M.K., Li Y., Murphy B. et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23(15):3562–7. DOI: 10.1200/JCO.2005.01.057.
11. Fan Z., Baselga J., Masui H., Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993;53(19):4637–42.
12. Vermorken J.B., Mesía R., Rivera F. et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116–27. DOI: 10.1056/NEJMoa0802656.
13. Vermorken J.B., Psyrri A., Mesía R. et al. Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial. Ann Oncol 2014;25(4):801–7. DOI: 10.1093/annonc/mdt574.
14. Fullerton Z.H., Butler S.S., Mahal B.A. et al. Short-term mortality risks among patients with oropharynx cancer by human papillomavirus status. Cancer 2020;126(7): 1424–33. DOI: 10.1002/cncr.32652.
15. Guigay J., Mesia R., Bourhis J. et al. TPExtreme randomized trial: TPEx versus EXTREME regimen in 1 line recurrent/ metastatic head and neck squamous cell carcinoma. J Clin Oncol 2015;33(15 Suppl): TPS6087. DOI: 10.1200/jco.2015.33.15_suppl.tps6087.
16. Ferris R.L., Blumenschein G. Jr, Fayettee J. et al. Nivolumab for recurrent squamous cell carcinoma of the head and neck. N Engl J Med 2016;375(19):1856–67. DOI: 10.1056/NEJMoa1602252.
17. Cohen E.E.W., Harrington K.J., Tourneau C.L. et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 2019;393(10167):156–67. DOI: 10.1016/S0140-6736(18)31999-8.
18. Rischin D., Harrington K.J., Greil R. et al. Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). J Clin Oncol 2019;37(suppl):6000.
Review
For citations:
Bolotina L.V., Deshkina T.I., Kornietskaya A.L., Kravtsov S.A., Ustinova T.V., Paychadze A.A., Kaprin A.D., Fedenko А.А. Influence of the results of international studies on the choice of treatment tactics for unresectable forms of squamous cell carcinoma of the head and neck. Head and Neck Tumors (HNT). 2020;10(2):10-21. (In Russ.) https://doi.org/10.17650/2222-1468-2020-10-2-10-21
Views:
731
Email this article 